SCHEMBL4521437

SCHEMBL4521437

CCCCn1c(Cc2ccc(Cl)c(Cl)c2)nc2sc(CC(=O)O)c(C)c2c1=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
ADORA3 P0DMS8 1/20 0.36
ADORA2B P29275 1/20 0.36
PTGDR2 Q9Y5Y4 3/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
RNASEH1 O60930 1/20 0.34
AGTR1 P30556 2/20 0.34
AGTR2 P50052 2/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494840 0.75 RNASEH1 (0.54) MAPTRNASEH1SMN1; SMN2
SCHEMBL4511109 0.74 P2RX3 (0.36) CNR1CNR2MAPTRNASEH1CYP1A2
SCHEMBL4511604 0.73 RNASEH1 (0.35) CNR1CNR2MAPTRNASEH1CYP1A2
SCHEMBL3494017 0.73 LMNA (0.46) TP53MAPTRNASEH1
SCHEMBL3492404 0.70 LMNA (0.44) TP53MAPTRNASEH1SMN1; SMN2
SCHEMBL4519168 0.70 KMT2A (0.48) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4521433 0.69 ALDH1A1 (0.46) MAPTRNASEH1SMN1; SMN2
SCHEMBL3491779 0.66 RNASEH1 (0.50) MAPTRNASEH1SMN1; SMN2
SCHEMBL3494138 0.66 RNASEH1 (0.52) MAPTRNASEH1SMN1; SMN2
SCHEMBL4511602 0.62 HPGD (0.45) MAPTRNASEH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 CNR1 575/4885CNR2 391/4885ADORA3 898/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 CNR1 575/4885CNR2 391/4885ADORA3 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.